NCT05001373View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

July 1, 2024

Conditions
Hiv
Interventions
BIOLOGICAL

Core-g28v2 60mer mRNA Vaccine

100µg, Intramuscularly

BIOLOGICAL

eOD-GT8 60mer mRNA Vaccine

100µg, Intramuscularly

Trial Locations (4)

20052

George Washington University, Washington D.C.

30322

Emory University, Atlanta

78229

UT Health San Antonio, San Antonio

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

ModernaTX, Inc.

INDUSTRY

collaborator

George Washington University

OTHER

collaborator

Fred Hutchinson Cancer Center

OTHER

collaborator

Emory University

OTHER

collaborator

UT Health San Antonio

UNKNOWN

lead

International AIDS Vaccine Initiative

NETWORK